No Prescription |
 |
 | ||
|
Methycobal Generic Mecobalamin |
|
| ||
No Prescription » Prescription Drugs 10 » Methycobal Generic Mecobalamin Methycobal is Vitamin B12 Substance.Methycobalamin is the neurologically active form of vitamin B12. Used in the treatment of Alcoholic neuropathy Drug induced neuropathy Diabetic neuropathy Peripheral neuropathy. Buy Methycobal Generic Mecobalamin and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About Methycobal Generic Mecobalamin: Product Type: Prescription Drugs 10 Methycobal ( Generic Mecobalamin ) Methycobal (Generic Mecobalamin) Generic Mecobalamin 500mcg Generic Mecobalamin Methycobal
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
